Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player of lipid metabolism with higher plasma levels in women throughout their life. Statin treatment affects PCSK9 levels also showing evidence of sex-differential effects. It remains unclear whether these differences can be explained by genetics. Methods We performed genome-wide association meta-analyses (GWAS) of PCSK9 levels stratified for sex and statin treatment in six independent studies of Europeans (8936 women/11,080 men respectively 14,825 statin-free/5191 statin-treated individuals). Loci associated in one of the strata were tested for statin- and sex-interactions considering all independent signals per locus. Independent variants at the PCSK9 gene locus were then used in a stratified Mendelian Randomization analysis (cis-MR) of PCSK9 effects on low-density lipoprotein cholesterol (LDL-C) levels to detect differences of causal effects between the subgroups. Results We identified 11 loci associated with PCSK9 in at least one stratified subgroup (p < 1.0 × $ 10^{–6} $), including the PCSK9 gene locus and five other lipid loci: APOB, TM6SF2, FADS1/FADS2, JMJD1C, and HP/HPR. The interaction analysis revealed eight loci with sex- and/or statin-interactions. At the PCSK9 gene locus, there were four independent signals, one with a significant sex-interaction showing stronger effects in men (rs693668). Regarding statin treatment, there were two significant interactions in PCSK9 missense mutations: rs11591147 had stronger effects in statin-free individuals, and rs11583680 had stronger effects in statin-treated individuals. Besides replicating known loci, we detected two novel genome-wide significant associations: one for statin-treated individuals at 6q11.1 (within KHDRBS2) and one for males at 12q24.22 (near KSR2/NOS1), both with significant interactions. In the MR of PCSK9 on LDL-C, we observed significant causal estimates within all subgroups, but significantly stronger causal effects in statin-free subjects compared to statin-treated individuals. Conclusions We performed the first double-stratified GWAS of PCSK9 levels and identified multiple biologically plausible loci with genetic interaction effects. Our results indicate that the observed sexual dimorphism of PCSK9 and its statin-related interactions have a genetic basis. Significant differences in the causal relationship between PCSK9 and LDL-C suggest sex-specific dosages of PCSK9 inhibitors..
Plain English Summary The protein “proprotein convertase subtilisin/kexin type 9” (PCSK9) regulates the levels of low-density lipoprotein cholesterol (LDL-C) in blood, and thus, contributes to the risk of cardio-vascular diseases. Women tend to have higher PCSK9 plasma levels throughout their life, although the difference is smaller in patients under LDL-C lowering medication (e.g., statins). We investigated the interplay of genetics, statin-treatment and sex, using combined data from six European studies. We detected 11 genetic regions associated with PCSK9 levels, of which one was specific for women (at SLCO1B3, a statin-transporter gene), and three were specific for men (e.g., ALOX5, encoding a protein linked to chronic inflammatory diseases such as atherosclerosis). We also tested if statin use changed the genetic effect and found five genes only associated with PCSK9 levels in untreated participants. Variants in the gene encoding PCSK9 were most strongly associated and had heterogeneous effects in dependence on statin treatment and sex: On one hand, there were genetic variants with stronger effects in men than women. Those variants are also linked to sex-differential gene expression of PCSK9. On the other hand, there were also variants with treatment-depending effects, linked to protein structure and functionality of PCSK9. This indicates that the observed sexual and treatment-related effects on PCSK9 levels have a genetic basis. In addition, we compared the causal effects of PCSK9 on LDL-C levels between men and women and found a different response to statin treatment. This highlights the need for sex-sensitive dosages of lipid-lowering medication..
Highlights First sex- and statin-stratified GWAS of PCSK9 plasma levels comparing SNP effects in eight subgroups.11 associated loci (p < 1 × $ 10^{–6} $), including six loci known for association with PCSK9 or lipids, and five novel loci independent of lipids.Five loci with significant sex-interactions, and seven loci with statin-interactions.The PCSK9 gene was associated in all subgroups, and there were both significant sex- and statin-related effects.The Mendelian Randomization using four independent PCSK9 variants resulted in significant causal estimates for all subgroups. The causal estimates of statin-treated individuals were significantly lower than those of statin-free participants. This difference increased testing the subgroup of men, and decreased in women..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Biology of sex differences - 15(2024), 1 vom: 26. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pott, Janne [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13293-024-00602-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055310591 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055310591 | ||
| 003 | DE-627 | ||
| 005 | 20240327065057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13293-024-00602-6 |2 doi | |
| 035 | |a (DE-627)SPR055310591 | ||
| 035 | |a (SPR)s13293-024-00602-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 610 |q VZ |
| 100 | 1 | |a Pott, Janne |e verfasserin |0 (orcid)0000-0002-5983-5331 |4 aut | |
| 245 | 1 | 0 | |a Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player of lipid metabolism with higher plasma levels in women throughout their life. Statin treatment affects PCSK9 levels also showing evidence of sex-differential effects. It remains unclear whether these differences can be explained by genetics. Methods We performed genome-wide association meta-analyses (GWAS) of PCSK9 levels stratified for sex and statin treatment in six independent studies of Europeans (8936 women/11,080 men respectively 14,825 statin-free/5191 statin-treated individuals). Loci associated in one of the strata were tested for statin- and sex-interactions considering all independent signals per locus. Independent variants at the PCSK9 gene locus were then used in a stratified Mendelian Randomization analysis (cis-MR) of PCSK9 effects on low-density lipoprotein cholesterol (LDL-C) levels to detect differences of causal effects between the subgroups. Results We identified 11 loci associated with PCSK9 in at least one stratified subgroup (p < 1.0 × $ 10^{–6} $), including the PCSK9 gene locus and five other lipid loci: APOB, TM6SF2, FADS1/FADS2, JMJD1C, and HP/HPR. The interaction analysis revealed eight loci with sex- and/or statin-interactions. At the PCSK9 gene locus, there were four independent signals, one with a significant sex-interaction showing stronger effects in men (rs693668). Regarding statin treatment, there were two significant interactions in PCSK9 missense mutations: rs11591147 had stronger effects in statin-free individuals, and rs11583680 had stronger effects in statin-treated individuals. Besides replicating known loci, we detected two novel genome-wide significant associations: one for statin-treated individuals at 6q11.1 (within KHDRBS2) and one for males at 12q24.22 (near KSR2/NOS1), both with significant interactions. In the MR of PCSK9 on LDL-C, we observed significant causal estimates within all subgroups, but significantly stronger causal effects in statin-free subjects compared to statin-treated individuals. Conclusions We performed the first double-stratified GWAS of PCSK9 levels and identified multiple biologically plausible loci with genetic interaction effects. Our results indicate that the observed sexual dimorphism of PCSK9 and its statin-related interactions have a genetic basis. Significant differences in the causal relationship between PCSK9 and LDL-C suggest sex-specific dosages of PCSK9 inhibitors. | ||
| 520 | |a Plain English Summary The protein “proprotein convertase subtilisin/kexin type 9” (PCSK9) regulates the levels of low-density lipoprotein cholesterol (LDL-C) in blood, and thus, contributes to the risk of cardio-vascular diseases. Women tend to have higher PCSK9 plasma levels throughout their life, although the difference is smaller in patients under LDL-C lowering medication (e.g., statins). We investigated the interplay of genetics, statin-treatment and sex, using combined data from six European studies. We detected 11 genetic regions associated with PCSK9 levels, of which one was specific for women (at SLCO1B3, a statin-transporter gene), and three were specific for men (e.g., ALOX5, encoding a protein linked to chronic inflammatory diseases such as atherosclerosis). We also tested if statin use changed the genetic effect and found five genes only associated with PCSK9 levels in untreated participants. Variants in the gene encoding PCSK9 were most strongly associated and had heterogeneous effects in dependence on statin treatment and sex: On one hand, there were genetic variants with stronger effects in men than women. Those variants are also linked to sex-differential gene expression of PCSK9. On the other hand, there were also variants with treatment-depending effects, linked to protein structure and functionality of PCSK9. This indicates that the observed sexual and treatment-related effects on PCSK9 levels have a genetic basis. In addition, we compared the causal effects of PCSK9 on LDL-C levels between men and women and found a different response to statin treatment. This highlights the need for sex-sensitive dosages of lipid-lowering medication. | ||
| 520 | |a Highlights First sex- and statin-stratified GWAS of PCSK9 plasma levels comparing SNP effects in eight subgroups.11 associated loci (p < 1 × $ 10^{–6} $), including six loci known for association with PCSK9 or lipids, and five novel loci independent of lipids.Five loci with significant sex-interactions, and seven loci with statin-interactions.The PCSK9 gene was associated in all subgroups, and there were both significant sex- and statin-related effects.The Mendelian Randomization using four independent PCSK9 variants resulted in significant causal estimates for all subgroups. The causal estimates of statin-treated individuals were significantly lower than those of statin-free participants. This difference increased testing the subgroup of men, and decreased in women. | ||
| 650 | 4 | |a PCSK9 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GWAS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sex |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Statin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interaction |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kheirkhah, Azin |4 aut | |
| 700 | 1 | |a Gadin, Jesper R. |4 aut | |
| 700 | 1 | |a Kleber, Marcus E. |4 aut | |
| 700 | 1 | |a Delgado, Graciela E. |4 aut | |
| 700 | 1 | |a Kirsten, Holger |4 aut | |
| 700 | 1 | |a Forer, Lukas |4 aut | |
| 700 | 1 | |a Hauck, Stefanie M. |4 aut | |
| 700 | 1 | |a Burkhardt, Ralph |4 aut | |
| 700 | 1 | |a Scharnagl, Hubert |4 aut | |
| 700 | 1 | |a Loeffler, Markus |4 aut | |
| 700 | 1 | |a März, Winfried |4 aut | |
| 700 | 1 | |a Thiery, Joachim |4 aut | |
| 700 | 1 | |a Gieger, Christian |4 aut | |
| 700 | 1 | |a Peters, Annette |4 aut | |
| 700 | 1 | |a Silveira, Angela |4 aut | |
| 700 | 1 | |a Hooft, Ferdinand van’t |4 aut | |
| 700 | 1 | |a Kronenberg, Florian |4 aut | |
| 700 | 1 | |a Scholz, Markus |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biology of sex differences |d BioMed Central, 2010 |g 15(2024), 1 vom: 26. März |w (DE-627)SPR031233783 |w (DE-600)2587352-0 |x 2042-6410 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:26 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13293-024-00602-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 26 |c 03 | ||